Topic

Articles

Successful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.

The Current Status of European Research Related to COVID-19: The EUCROF Perspective

Evolving technologies include modification of receptors on T cells to better target tumor microenvironments and minimize off-tumor cross-reactivity. 

Facilitating Adoptive Cell Therapy Clinical Trials

87% of people surveyed said they had no concerns about a decentralized approach to clinical trials. 

Recent Data Shows Positive Attitudes for Decentralized Trials in Rare Disease Patients

Sangamo executives, Melita Sun Jung and Amy Pooler, discuss the future of genomic medicines for autism spectrum disorder.

A New Interest in Autism Genomic Therapy Development 

Moe Alsumidaie sits down with Ping Yeh, CEO and co-founder of StemoniX, to discuss how MicroOrgans will transform preclinical and clinical development in challenging areas like Alzheimer’s.

The Future of Clinical Development is Here: Research in MicroOrgans

Newest revelations suggest Risk Assessment Categorization Tools are now becoming therapeutic area-specific, as an oncology-based risk library is now surfacing.

Oncology Therapy-Focused RACT Emerges

Examining the unique standards and related challenges when assessing the safety and efficacy of cancer immunotherapy candidates.

Maximizing Immuno-Oncology Clinical Trial Success

The ability to diagnose cancer at earlier stages of the disease is constrained by the specificity and mechanics of traditional diagnostic methods. The growing use of liquid biopsy technology may help overcome such barriers and potentially revolutionize cancer research, patient treatment, and survivor care.

The Promise of Liquid Biopsy Technology

Examining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens. 

Mitigating Risk in Implementing Multi-Regional Trials in MS

To vie for success in the market for dermatologic therapies, companies developing biologics must navigate a series of significant challenges, including patient compliance and safety.

Therapeutic Areas